[Portfolio news] We’re proud to announce that Augustine Therapeutics has raised a €17 million ($18.5 million) #SeriesA to develop its pipeline for neurodegenerative and cardiometabolic diseases. Warm welcome to our new partners, Asabys Partners, Eli Lilly and Company, and CMT Research Foundation & to Gerhard Koenig, Chairman of the board. Alain Huriez Adrien C. Sylvain Celanire
NEWS ALERT! 📢 We are excited to announce the completion of a €17 million ($18.5 million) Series A first close to advance our differentiated HDAC6 inhibitor pipeline to the clinic and support expansion of our R&D and management team. This funding round is led by Asabys Partners, with the participation of Eli Lilly and Company and the US CMT Research Foundation, alongside continued support from our historical investors PMV, AdBio partners, V-Bio Ventures, VIB and GEMMA FRISIUS - FONDS K.U.LEUVEN. As part of this milestone, we welcome Clara Campàs Moya, Managing Partner and co-founder of Asabys Partners, to the Augustine Board of Director, and announce the appointment of Gerhard Koenig as executive Chairman. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program! To learn more, read the full press release here: https://lnkd.in/eVtvQUdv #AugustineTx #SeriesA #CMT